Holen Sie sich die Stockscreener-App
32.38
3.57%
-1.20
Handel nachbörslich:
32.37
-0.01
-0.03%
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
(RAPP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform? - simplywall.st
Rapport Therapeutics, Inc. (RAPP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting - Sahm
Rapport Therapeutics to present epilepsy trial data at AAN By Investing.com - au.investing.com
Rapport Therapeutics to present epilepsy trial data at AAN - Investing.com
Rapport's new 8-week seizure data heads to a major neurology meeting - Stock Titan
Market Catalysts: Is Rapport Therapeutics Inc a good stock for dollar cost averaging2026 Growth vs Value & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Rapport Therapeutics COO Gault sells $281k in stock By Investing.com - Investing.com South Africa
Rapport Therapeutics COO Gault sells $281k in stock - investing.com
Rapport Therapeutics Insider Sold Shares Worth $281,857, According to a Recent SEC Filing - marketscreener.com
Rapport Therapeutics (RAPP) COO sells 10,000 shares under Rule 10b5-1 plan - Stock Titan
10,000-share Rule 144 sale by RAPP (NASDAQ: RAPP) lists $278,400 value - Stock Titan
Patterns Watch: What is the cash position of Rapport Therapeutics IncMarket Sentiment Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Aug Ideas: What hedge funds are buying Rapport Therapeutics Inc2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Will Rapport Therapeutics Inc benefit from AI trendsPortfolio Gains Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Will Rapport Therapeutics' RAP-219 Deliver A Pipeline-in-a-Product Story? - RTTNews
Yeleswaram, Rapport Therapeutics chief development officer, sells $303k By Investing.com - au.investing.com
Rapport Therapeutics (NASDAQ:RAPP) Raised to “Strong-Buy” at Truist Financial - defenseworld.net
Yeleswaram, Rapport Therapeutics chief development officer, sells $303k - Investing.com
Rapport Therapeutics Insider Sold Shares Worth $303,355, According to a Recent SEC Filing - MarketScreener
Rapport Therapeutics (RAPP) CDO sells 10,115 shares under 10b5-1 plan - Stock Titan
All Essential Information Regarding Rapport Therapeutics, Inc. (RAPP) Rating Raised to Buy - Bitget
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy - sharewise.com
Rapport Therapeutics (NASDAQ:RAPP) Upgraded at Truist Financial - MarketBeat
RAPP (NASDAQ: RAPP) insider sale reported: 2,840 common shares - Stock Titan
Geopolitics Watch: Will Rapport Therapeutics Inc stock go up in YEAR2026 Price Targets & AI Driven Price Predictions - baoquankhu1.vn
(RAPP) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
RAPP SEC FilingsRapport Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RAPP Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Aug Selloffs: Why is Rapport Therapeutics Inc stock going up2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Buyout Rumor: Does Rapport Therapeutics Inc have strong fundamentals2026 Highlights & Long-Term Capital Growth Strategies - baoquankhu1.vn
Sell Signal: Will Rapport Therapeutics Inc benefit from AI trends2026 Drop Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Update Recap: Why is Rapport Therapeutics Inc stock going up2026 Volume Leaders & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Whats the outlook for Rapport Therapeutics Incs sectorWeekly Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Take Profit: Is Rapport Therapeutics Inc undervalued by DCF analysisWeekly Loss Report & Stock Portfolio Risk Management - baoquankhu1.vn
Truist reiterates Rapport Therapeutics stock rating on phase 3 plans By Investing.com - ca.investing.com
Truist reiterates Rapport Therapeutics stock rating on phase 3 plans - Investing.com
Baker BROS. Advisors LP Has $45.95 Million Position in Rapport Therapeutics, Inc. $RAPP - MarketBeat
HC Wainwright & Co. Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - msn.com
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Why Rapport Therapeutics (RAPP) Is Down 7.9% After RAP-219 China Deal And Shelf Filing - simplywall.st
Q1 EPS Forecast for Rapport Therapeutics Boosted by Analyst - Defense World
Q1 EPS Estimate for Rapport Therapeutics Lifted by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail
(RAPP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives $50.80 Consensus PT from Brokerages - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.7%Should You Sell? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Equities Analysts Offer Predictions for RAPP FY2030 Earnings - MarketBeat
Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Day Trade: Will Rapport Therapeutics Inc stock go up in YEARMarket Weekly Review & Scalable Portfolio Growth Methods - baoquankhu1.vn
Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $46.00 at Wells Fargo & Company - MarketBeat
BTIG raises Rapport Therapeutics stock price target on trial progress By Investing.com - Investing.com Canada
Jones Trading reiterates Rapport Therapeutics stock rating on epilepsy progress - Investing.com Canada
Stifel reiterates Rapport Therapeutics stock rating after results By Investing.com - Investing.com Canada
Rapport Therapeutics Inc (RAPP) Reports a Wider Loss for Q4 2025 - AlphaStreet
Rapport Therapeutics Reports Strong 2025 Results, Advances RAP-219 Epilepsy Drug to Phase 3 with $490M Cash Runway - Minichart
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):